bortezomib
first
therapeut
proteasom
inhibitor
one
primari
agent
treatment
multipl
myeloma
mm
select
revers
inhibit
proteolyt
activ
proteasom
complex
block
ubiquitinproteasom
pathway
bortezomib
market
china
sinc
wide
use
treatment
mm
thereaft
signific
improv
mm
treatment
term
clinic
efficaci
longterm
surviv
rate
observ
sinc
use
bortezomib
immunomodul
improv
hematopoiet
stem
cell
transplant
bortezomib
signific
antimyeloma
activ
manag
toxic
common
advers
effect
includ
gastrointestin
symptom
peripher
neuropathi
neuropath
pain
thrombocytopenia
demonstr
bortezomib
significantli
associ
high
incid
herp
zoster
howev
effect
bortezomib
hepat
b
viru
hbv
remain
unclear
hbv
reactiv
report
case
treatment
bortezomib
efficaci
safeti
evid
bortezomib
mm
patient
hbv
infect
vacant
year
retrospect
analysi
perform
aim
studi
evalu
safeti
efficaci
bortezomib
treatment
mm
patient
hbv
china
patient
includ
mm
center
met
diagnosi
criteria
guidelin
diagnosi
treatment
multipl
myeloma
revis
edit
bone
marrow
collect
plasma
cell
count
immunophenotyp
analysi
cytogenet
analysi
interphas
fluoresc
situ
hybrid
interphas
fish
analysi
hbv
virolog
test
result
baselin
also
collect
mm
patient
immunophenotyp
analys
perform
patient
use
fourcolor
direct
immunofluoresc
stain
identifi
immunophenotyp
clonal
plasma
cell
erythrocytelys
bone
marrow
sampl
fluoresc
wherea
panel
high
risk
cytogenet
abnorm
defin
least
abnorm
routin
cytogenet
analysi
fish
perform
interphas
nuclei
includ
amplif
delet
delet
delet
igh
rearrang
minimum
interphas
cell
analyz
probe
patient
screen
presenc
hbv
surfac
antigen
hbsag
surfac
antibodi
e
antigen
hbeag
e
antibodi
hbeab
core
antibodi
hbcab
hbv
dna
load
prophylaxi
hbv
reactiv
nucleosid
analogu
oral
administ
hbsag
patient
long
antimyeloma
treatment
initi
continu
year
treatment
stop
mg
lamivudin
per
day
case
mg
entecavir
per
day
case
five
hbsag
patient
receiv
prophylact
therapi
hbv
biochem
index
liver
renal
function
electrolyt
blood
glucos
coagul
function
examin
twice
weekli
treatment
weekli
treatment
quantif
hbv
dna
detect
monthli
polymeras
chain
reaction
treatment
european
group
blood
marrow
transplant
criteria
use
defin
complet
respons
cr
partial
respons
pr
minim
respons
relaps
progress
mm
patient
continu
variabl
describ
mean
standard
deviat
sd
alanin
transaminas
alt
differ
mm
patient
hbv
bortezomib
treatment
analyz
pair
ttest
percentag
differ
patient
undetect
hbv
dna
copiesml
evalu
chisquar
test
statist
analys
perform
use
spss
softwar
spss
inc
chicago
il
usa
p
consid
statist
signific
among
mm
patient
infect
hbv
preval
hbv
infect
mm
patient
seventeen
hbvinfect
patient
receiv
bortezomib
agent
therapi
patient
got
bortezomib
combin
dexamethason
regim
patient
got
pad
bortezomib
combin
dexamethason
epirubicin
patient
got
bortezomib
combin
dexamethason
thalidomid
patient
got
bortezomib
combin
dexamethason
cyclophosphamid
patient
got
bdcep
dose
bortezomib
day
dose
dexamethason
mgd
dose
epirubicin
dose
cyclophosphamid
mgd
bdcep
regim
dexamethason
mgd
cyclophosphamid
etoposid
cisplatin
dose
bortezomib
show
among
patient
got
bortezomib
hbv
carrier
patient
diagnos
chronic
hepat
b
hepat
b
liver
cirrhosi
among
patient
inact
hbsag
carrier
hbsag
hbeab
hbcab
normal
alt
patient
chronic
hbv
carrier
hbsag
hbeag
hbcab
normal
alt
hbv
dna
load
copiesml
chronic
hbv
carrier
also
infect
hepat
c
identifi
abnorm
hepat
c
messeng
rna
characterist
mm
patient
hbv
shown
tabl
identifi
influenc
bortezomib
liver
function
evalu
alt
level
mm
patient
hbv
bortezomib
treatment
cycl
signific
differ
mean
alt
level
identifi
treatment
bortezomib
ul
vs
ul
p
find
influenc
bortezomib
detect
hbv
dna
percentag
analyz
percentag
patient
detect
hbv
dna
percentag
signific
differ
percentag
patient
detect
hbv
dna
bortezomib
treatment
cycl
vs
p
patient
case
achiev
cr
case
achiev
pr
respons
rate
type
stage
mm
hbvinfect
patient
similar
nonhbvinfect
patient
use
interphas
fish
incid
mm
patient
hbv
mm
patient
without
hbv
incid
amplif
hbv
patient
without
hbv
hbv
patient
high
risk
chromosom
g
band
rate
without
hbv
posit
rate
among
patient
without
hbv
versu
versu
versu
respect
posit
rate
patient
without
hbv
versu
versu
respect
three
patient
die
diseas
progress
wherea
die
lung
infect
relat
liver
failur
hepat
impair
median
overal
surviv
os
month
month
chronic
hbv
infect
may
increas
risk
lymphoid
malign
signific
associ
found
hbv
mm
engel
report
test
hbsag
among
peopl
health
screen
hbsag
subject
elev
risk
nhl
mm
incid
mm
per
year
hbsag
popul
wherea
per
year
popul
anoth
studi
guangdong
provinc
china
hbsag
rate
significantli
higher
mm
patient
acut
leukemia
patient
higher
averag
incid
hepat
b
announc
chines
center
diseas
control
china
cdc
controversi
may
come
region
differ
nest
studi
europ
studi
epic
hbv
carrier
among
control
differ
countri
rang
statist
signific
associ
found
hbsag
seroposit
risk
mm
odd
ratio
confid
interv
followup
due
lower
preval
hepat
b
europ
hbsag
mm
patient
treatment
group
control
group
studi
may
lead
misjudg
due
small
sampl
size
asia
highli
endem
region
hbv
infect
pattern
hepat
b
preval
differ
among
region
data
patient
studi
two
mm
treatment
center
beij
patient
part
countri
repres
actual
statu
epidem
characterist
mm
patient
china
preval
hbsag
mm
patient
studi
lower
result
singapor
studi
studi
hbcab
patient
also
consid
affect
hepat
b
infect
studi
exclud
kind
patient
due
potenti
abort
infect
postinfect
use
bortezomib
hbv
reactiv
even
fulmin
hepat
failur
report
mm
patient
one
case
mm
patient
consid
replic
phase
chronic
hepat
b
hbsag
hbeag
serum
hbv
dna
level
copiesml
normal
transferas
level
treat
four
cycl
vincristin
doxorubicin
dexamethason
eight
cycl
bortezomib
hbv
dna
neg
aminotransferas
found
normal
therapi
hepat
b
reactiv
demonstr
hbv
dna
level
copiesml
month
bortezomib
therapi
unabl
judg
causal
relationship
hbv
reactiv
bortezomib
patient
die
fulmin
hepat
studi
singapor
hbv
reactiv
case
report
month
bortezomib
dexamethason
treatment
relationship
reactiv
bortezomib
unclear
proteasom
play
import
role
viru
life
cycl
proteasom
inhibitor
bortezomib
antivir
activ
kind
virus
despit
antitumor
activ
bortezomib
could
inhibit
duplic
fibroblast
cell
vitro
mous
studi
mgkg
bortezomib
could
decreas
copi
hbv
transgen
mous
vivo
studi
inhibit
activ
disappear
concentr
mgkg
howev
concentr
increas
mgkg
decreas
howev
increas
copi
viru
increas
alt
level
higher
dose
group
seen
day
bortezomib
treatment
return
normal
day
indic
increas
caus
viru
replic
opposit
result
seen
mous
hbv
infect
vivo
model
mgkg
bortezomib
treat
mice
increas
mous
hbv
replic
due
inhibit
immun
cell
controversi
result
two
studi
might
deriv
specif
immun
statu
transgen
mice
mm
patient
whose
immun
function
inhibit
immunedefici
might
similar
immun
condit
transgen
mice
present
studi
bortezomib
impact
hbv
reactiv
liver
function
mm
patient
howev
unclear
whether
bortezomib
therapi
increas
decreas
viru
replic
mm
patient
hbv
infect
studi
specif
anim
model
need
elucid
question
patient
respons
rate
similar
result
patient
previou
trial
amplif
interphas
fish
common
hbsag
patient
immunophenotyp
increas
express
express
may
play
import
role
b
cell
abnorm
induc
hbv
mm
eventu
yet
underli
mechan
remain
unclear
due
small
sampl
size
patient
immunophenotyp
cytogenet
determin
studi
need
accord
previou
report
risk
hbv
reactiv
mm
patient
highest
month
asct
immun
reconstitut
phase
although
reconstitut
cytotox
hbvspecif
tcell
never
studi
like
reconstitut
hbv
whose
specif
cytotox
tcell
substanti
reduc
first
month
transplant
remark
recov
month
transplant
use
thalidomid
recommend
mainten
set
asct
fact
vitro
thalidomid
could
act
tcell
costimul
enhanc
virusspecif
tcell
cytokin
product
cytotox
activ
mean
immun
recoveri
phase
even
profound
induc
accur
hepat
injuri
bortezomib
could
impair
sever
immun
properti
human
monocytederiv
dendrit
cell
dc
suppress
essenti
immun
function
human
tcell
activ
allogen
dc
despit
potenti
immunemodulatori
effect
still
unclear
bortezomib
could
induc
hbv
reactiv
sever
limit
unavoid
studi
first
sampl
size
small
mm
patient
hbv
includ
final
analysi
second
analys
perform
cycl
clear
differ
follow
cycl
last
least
retrospect
studi
select
bia
may
impact
final
result
therefor
perspect
studi
larg
sampl
size
togeth
analysi
multipl
cycl
perform
futur
conclus
studi
indic
higher
preval
hbv
infect
mm
patient
efficaci
bortezomib
among
mm
patient
hbv
infect
compar
studi
hbv
reactiv
observ
patient
treatment
lamivudin
entecavir
prophylaxi
antiviru
nucleosid
nucleotid
analog
recommend
treatment
bortezomib
hbsag
mm
patient
nil
conflict
interest
